$BCAX

BTIG maintained a Buy rating on Bicara Therapeutics with a $39 price target, suggesting 132.4% upside from the Oct 16 close. The firm highlights ficerafusp alfa's superior efficacy and $993M peak sales potential in head and neck cancer.

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 - Entry into a Material Definitive Agreement. On August 21, 2026, Bicara Therapeutics Inc. (the “Company”) entered into a Sub-Sublease Agreement (the “Sublease”) with Wayfair LLC, as sublandlord (the “Sublandlord”), pursuant to which the Company, as subtenant, will leas

Bicara Therapeutics (BCAX) reported 3-year data for ficerafusp alfa, showing improved survival rates in HPV-negative head and neck cancer. The company is on track for a pivotal trial readout in mid-2027. CEO Claire Mazumdar will step down, with leadership changes taking effect in early 2024. Operating expenses are rising ahead of potential revenue.

Bicara Therapeutics (BCAX) reported Q2 2026 earnings, highlighting $497.3M in cash and marketable securities, a net loss of $55.4M, and R&D expenses of $45.8M. The company is on track for FORTIFI-HN01 study enrollment by year-end 2026, with interim analysis expected in mid-2027. Management discussed leadership transitions and strategic focus on HPV-negative head and neck cancer, as well as exploratory colorectal cancer cohorts.

Bicara Therapeutics reported Q2 2026 earnings call updates. Management said CEO transition to Ryan Cohlhepp is planned as the company advances Phase III FORTIFI-HN01 in HPV-negative head and neck cancer, with substantial enrollment expected by end-2026. ASCO 2026 data showed TGF-beta inhibition nearly doubled overall survival vs pembrolizumab in the pivotal dose cohort. Cash was $497M, funding into 1H 2029.

Bicara Therapeutics (NASDAQ:BCAX) shares rose about 3.3% pre-market after the company said enrollment is progressing in its pivotal FORTIFI-HN01 study and it remains on track for an interim analysis in mid-2027. Bicara reported Q2 2026 net loss of $55.4M, or $0.82 per share, with higher R&D and G&A. Cash and securities were $497.3M, expected to fund operations into 1H 2029.

Cohlhepp Ryan (President and COO) sold 18,750 shares of Bicara Therapeutics Inc. (BCAX) at $27.98 ($0.52M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Bicara Therapeutics (Nasdaq: BCAX) reported Q2 2026 progress and announced leadership changes. Ryan Cohlhepp will become CEO effective Jan 2027, succeeding Claire Mazumdar, who will move to Vice Chair and Strategic Advisor. Tanya Green becomes COO, and Jenn Larson becomes CFO. The company said it is on track for year-end enrollment in the FORTIFI-HN01 pivotal trial, with interim topline results expected mid-2027.

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. bcax-20260723 FALSE 0002023658 0002023658 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securitie